Improvements in No Evidence of Disease Activity with Ublituximab Vs. Teriflunomide in the ULTIMATE Phase 3 Studies in Relapsing Multiple Sclerosis
FRONTIERS IN NEUROLOGY（2024）
关键词
anti-CD20,disability,disease activity,disease-modifying therapy,multiple sclerosis,no evidence of disease activity,relapse,BRIUMVI
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要